Change search
ReferencesLink to record
Permanent link

Direct link
Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design
Guys and St Thomas Fdn Trust, England .
Eli Lilly and Co, France .
Karolinska University of Sjukhuset, Sweden .
Aberdeen Royal Infirm, Scotland .
Show others and affiliations
2013 (English)In: Health and Quality of Life Outcomes, ISSN 1477-7525, Vol. 11, no 163Article in journal (Refereed) Published
Abstract [en]


Home-based care in oncology is mainly reserved for patients at the end of life. Regulations regarding home delivery of cytotoxics differ across Europe, with a notable lack of practice guidelines in most countries. This has led to a lack of data addressing the feasibility of home-based administration of cytotoxic chemotherapy. In advanced non-squamous non-small cell lung cancer, pemetrexed is approved as maintenance therapy after first-line chemotherapy. In this setting, patients have the potential to be treated long-term with maintenance therapy, which, in the absence of unacceptable toxicity, is continued until disease progression. The favourable safety profile of pemetrexed and the ease of its administration by 10-minute intravenous infusion every 3 weeks make this drug a suitable candidate for administration in a home setting.


Literature and regulations relevant to the home-based delivery of cytotoxic therapy were reviewed, and a phase II feasibility study of home administration of pemetrexed maintenance therapy was designed. At least 50 patients with advanced non-squamous non-small cell lung cancer, Eastern Cooperative Oncology Group performance status 0–1 and no progressive disease after four cycles of platinum-based first-line therapy are required to allow investigation of the feasibility of home-based administration of pemetrexed maintenance therapy (500 mg/m2 every 3 weeks until progressive disease or unacceptable toxicity). Feasibility is being assessed as adherence to the home-based administration process (primary endpoint), patient safety, impact on patients’ quality of life, patient and physician satisfaction with home care, and healthcare resource use and costs. Enrolment of patients from the UK and Sweden, where home-based care is relatively well developed, commenced in December 2011.


This feasibility study addresses an important aspect of maintenance therapy, that is, patient comfort during protracted home-based chemotherapy. The study design requires unusual methodology and specific logistics to address outcomes relevant to the home-delivery approach. This article presents a study design that offers a novel and reproducible model for home-based chemotherapy, and provides an up-to-date overview of the literature regarding this type of treatment.

Place, publisher, year, edition, pages
BioMed Central , 2013. Vol. 11, no 163
Keyword [en]
Pemetrexed, Lung, Maintenance treatment, Home administration
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-102401DOI: 10.1186/1477-7525-11-163ISI: 000326568200003OAI: diva2:677364

Funding Agencies|Eli Lilly||

Available from: 2013-12-09 Created: 2013-12-09 Last updated: 2014-03-14

Open Access in DiVA

fulltext(486 kB)293 downloads
File information
File name FULLTEXT01.pdfFile size 486 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Vikström, Anders
By organisation
Department of Clinical and Experimental MedicineFaculty of Health SciencesDepartment of Respiratory Medicine
In the same journal
Health and Quality of Life Outcomes
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 293 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 48 hits
ReferencesLink to record
Permanent link

Direct link